|
US4350687A
(en)
|
1980-02-10 |
1982-09-21 |
Research Corporation |
Platelet derived cell growth factor
|
|
JPS60146833A
(ja)
|
1984-01-10 |
1985-08-02 |
Green Cross Corp:The |
モノクロ−ナル抗体製剤
|
|
JPS6178731A
(ja)
|
1985-05-20 |
1986-04-22 |
Green Cross Corp:The |
加熱処理免疫グロブリン製剤
|
|
CA1327161C
(en)
|
1987-09-01 |
1994-02-22 |
Mitsugu Kobayashi |
Lyophilized pharmaceutical composition of neocarzinostatin derivative
|
|
SE8801537D0
(sv)
|
1988-04-26 |
1988-04-26 |
Ellco Food Ab |
Cellodlingsmedium samt forfarande for dess framstellning
|
|
US5252713A
(en)
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
JPH04504253A
(ja)
|
1989-03-27 |
1992-07-30 |
セントカー・インコーポレーテツド |
ＩｇＭ抗体の安定化のための配合物
|
|
US5116944A
(en)
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
|
US5216130A
(en)
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
DE69722793T2
(de)
|
1996-04-26 |
2004-05-19 |
Genaera Corp. |
Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
|
|
GB9613182D0
(en)
|
1996-06-24 |
1996-08-28 |
Nycomed Imaging As |
Method
|
|
US6416967B2
(en)
|
1996-07-12 |
2002-07-09 |
Precision Therapeutics, Inc. |
Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
|
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
|
KR100904931B1
(ko)
|
1997-06-27 |
2009-06-29 |
아브락시스 바이오사이언스, 엘엘씨 |
나노 입자 및 그의 제조 방법
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US7041301B1
(en)
|
1997-11-07 |
2006-05-09 |
Mayo Foundation For Medical Education And Research |
Interferon immunotherapy
|
|
US6616925B1
(en)
|
1998-04-02 |
2003-09-09 |
I.D.M. Immuno-Designed Molecules |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
|
|
US7112409B2
(en)
|
1999-01-29 |
2006-09-26 |
Center For Molecular Medicine And Immunology |
Method of determining cytokine dosage for myelosuppressive state
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US6420378B1
(en)
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
|
DE10132502A1
(de)
|
2001-07-05 |
2003-01-23 |
Gsf Forschungszentrum Umwelt |
Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
|
|
IL164287A0
(en)
|
2002-04-12 |
2005-12-18 |
Medarex Inc |
Methods of treatment using ctla-4 antibodies
|
|
EP1578362A4
(en)
|
2002-07-09 |
2008-11-05 |
Point Therapeutics Inc |
COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
|
|
US20040265315A1
(en)
|
2002-09-05 |
2004-12-30 |
Christine Dingivan |
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
|
|
EP1545204B1
(en)
|
2002-09-06 |
2016-08-10 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
|
LT1585548T
(lt)
|
2002-12-09 |
2018-09-25 |
Abraxis Bioscience, Llc |
Farmakologinių agentų kompozicijos ir įvedimo būdai
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US8007782B2
(en)
|
2003-10-22 |
2011-08-30 |
The Johns Hopkins University |
Combination bacteriolytic therapy for the treatment of tumors
|
|
BRPI0509927A
(pt)
|
2004-04-22 |
2007-09-25 |
Lilly Co Eli |
composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
|
|
WO2005117952A2
(en)
*
|
2004-05-14 |
2005-12-15 |
Abraxis Bioscience, Inc. |
Treatment methods utilizing albumin-binding proteins as targets
|
|
US20060067930A1
(en)
*
|
2004-08-19 |
2006-03-30 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20060204512A1
(en)
|
2004-09-23 |
2006-09-14 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
|
JP2008515915A
(ja)
|
2004-10-07 |
2008-05-15 |
エモリー ユニバーシティー |
多機能性ナノ粒子結合体およびそれらの使用
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
US8735394B2
(en)
*
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
NZ595313A
(en)
|
2005-02-18 |
2013-03-28 |
Abraxis Bioscience Llc |
The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
|
|
US7976852B2
(en)
|
2005-04-26 |
2011-07-12 |
Eisai R&D Management Co., Ltd. |
Compositions and methods for cancer immunotherapy
|
|
US10183076B2
(en)
|
2005-05-16 |
2019-01-22 |
Resdevco Research And Development Co. L |
Topical compositions for treatment of irritation of mucous membranes
|
|
KR101643416B1
(ko)
|
2005-08-31 |
2016-07-27 |
아브락시스 바이오사이언스, 엘엘씨 |
증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
|
|
CA2880727C
(en)
|
2005-08-31 |
2019-05-07 |
Neil P. Desai |
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
|
|
US7776832B2
(en)
|
2006-04-21 |
2010-08-17 |
Gem Pharmaceuticals, Llc |
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
|
|
NZ576122A
(en)
|
2006-09-26 |
2012-09-28 |
Genmab As |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
EP2081687A2
(en)
|
2006-10-17 |
2009-07-29 |
Koninklijke Philips Electronics N.V. |
Device for amplification and detection of nucleic acids
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100112077A1
(en)
*
|
2006-11-06 |
2010-05-06 |
Abraxis Bioscience, Llc |
Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
|
|
AU2007317858A1
(en)
*
|
2006-11-07 |
2008-05-15 |
Dow Agrosciences Llc |
Sprayable, controlled-release, male annihilation technique (MAT) formulation and insect control method
|
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
|
KR20150002886A
(ko)
|
2007-03-07 |
2015-01-07 |
아브락시스 바이오사이언스, 엘엘씨 |
항암제로서 라파마이신 및 알부민을 포함하는 나노입자
|
|
WO2008112987A1
(en)
|
2007-03-14 |
2008-09-18 |
Mayo Foundation For Medical Education And Research |
Treating skin cancer
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
CA2700457A1
(en)
|
2007-10-01 |
2009-04-09 |
Austin Smith |
Neural tumor stem cells and methods of use thereof
|
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
|
WO2010118365A1
(en)
|
2009-04-10 |
2010-10-14 |
Abraxis Bioscience, Llc |
Nanoparticle formulations and uses therof
|
|
EP2310006A4
(en)
|
2008-07-03 |
2012-04-25 |
Mayo Foundation |
CANCER TREATMENT
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
US20110293576A1
(en)
|
2008-08-04 |
2011-12-01 |
Allocure Inc. |
Mesenchymal stromal cell populations and methods of isolating and using same
|
|
WO2010075540A1
(en)
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
CA2757645C
(en)
|
2009-04-06 |
2018-05-15 |
Mayo Foundation For Medical Education And Research |
Methods and materials for delivering molecules
|
|
US8571805B2
(en)
|
2009-04-10 |
2013-10-29 |
Pharmaco-Kinesis Corporation |
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
US20120076787A1
(en)
|
2009-05-28 |
2012-03-29 |
Peter Adamson |
Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
|
|
US8345535B2
(en)
*
|
2009-07-13 |
2013-01-01 |
Lg Electronics Inc. |
Method and apparatus for generating ranging preamble code in wireless communication system
|
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
BR112012010698A2
(pt)
|
2009-11-05 |
2016-11-29 |
Uab Research Foundation |
método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
|
|
JP2013510804A
(ja)
|
2009-11-13 |
2013-03-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
化学療法剤を装荷したナノ粒子に結合した抗インテグリン抗体
|
|
CN102740888B
(zh)
*
|
2009-11-24 |
2016-10-12 |
奥尔德生物制药公司 |
Il-6抗体及其用途
|
|
WO2011100403A1
(en)
*
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
EP3056201A1
(en)
|
2010-06-07 |
2016-08-17 |
Abraxis BioScience, LLC |
Combination therapy methods for treating proliferative diseases
|
|
US9466148B2
(en)
|
2010-09-03 |
2016-10-11 |
Disney Enterprises, Inc. |
Systems and methods to dynamically adjust an image on a display monitor represented in a video feed
|
|
WO2012048223A1
(en)
*
|
2010-10-08 |
2012-04-12 |
Abraxis Bioscience, Llc |
Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
|
|
US8992908B2
(en)
*
|
2010-11-23 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of oral mucositis
|
|
US20130281377A1
(en)
|
2010-12-23 |
2013-10-24 |
Mayo Foundation For Medical Education And Research |
Treating multiple myeloma
|
|
ES2792062T3
(es)
|
2011-05-09 |
2020-11-06 |
Mayo Found Medical Education & Res |
Tratamientos contra el cáncer
|
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
CA2855298A1
(en)
|
2011-11-09 |
2013-05-16 |
The Uab Research Foundation |
Her3 antibodies and uses thereof
|
|
US11471486B2
(en)
|
2012-09-04 |
2022-10-18 |
Inven2 As |
Selective and controlled expansion of educated NK cells
|
|
ES2899643T3
(es)
|
2012-10-01 |
2022-03-14 |
Mayo Found Medical Education & Res |
Tratamientos para el cáncer
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
SI3049441T1
(sl)
|
2013-09-27 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Formulacije protiteles proti PD-L1
|
|
AU2015274408A1
(en)
|
2014-06-13 |
2017-01-12 |
Mayo Foundation For Medical Education And Research |
Treating lymphomas
|
|
US10213513B2
(en)
|
2014-06-16 |
2019-02-26 |
Mayo Foundation For Medical Education And Research |
Treating myelomas
|
|
WO2016057554A1
(en)
|
2014-10-06 |
2016-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
MX2017007321A
(es)
|
2014-12-02 |
2017-08-25 |
Celgene Corp |
Terapias de combinacion.
|
|
CN114796130B
(zh)
|
2015-08-18 |
2023-10-20 |
梅约医学教育与研究基金会 |
载体结合剂组合物及其制备和使用方法
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
US11571469B2
(en)
|
2016-01-07 |
2023-02-07 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
|
|
US11351254B2
(en)
|
2016-02-12 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
CA3018341A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
WO2017165439A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for improving the therapeutic index for a chemotherapeutic drug
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
RU2019105550A
(ru)
|
2016-08-05 |
2020-09-07 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования
|
|
EP3506950A1
(en)
|
2016-09-01 |
2019-07-10 |
Mayo Foundation for Medical Education and Research |
Methods and compositions for targeting t-cell cancers
|
|
CA3035378A1
(en)
|
2016-09-01 |
2018-03-08 |
Mayo Foundation For Medical Education And Research |
Carrier-pd-l1 binding agent compositions for treating cancers
|
|
AU2017324335A1
(en)
|
2016-09-06 |
2019-03-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating PD-L1 expressing cancer
|
|
EP3509635A1
(en)
|
2016-09-06 |
2019-07-17 |
Vavotar Life Sciences LLC |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
EP3509643A1
(en)
|
2016-09-06 |
2019-07-17 |
Mayo Foundation for Medical Education and Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
|
JP7142915B2
(ja)
|
2016-10-28 |
2022-09-28 |
株式会社Ｓ＆Ｋバイオファーマ |
ラクトフェリン／アルブミン融合タンパク質及びその製造方法
|